Feed 2162.HK
21
Keymed Biosciences Inc.
2162.HK · HKSE
$78.40 +1.36% (+$1.05)
1M -11.30%
Market Cap ¥19.7B
P/E Ratio -
Div. Yield -
ROE 18.38%
Piotroski F-Score Weak
3/9Valuation
6 /100
Expensive P/B 7.10x
P/S 28.24x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 5.99%
Rev. growth 91.05%
FCF growth N/A
Profitability
20 /100
Weak Net margin 72.96%
Op. margin 83.82%
FCF margin 150.32%
Quality
2 /100
Poor ROE 18.38%
ROA 12.07%
Asset turnover 0.17x
Debt
69 /100
Low Current ratio 2.90x
Int. coverage -35.51x
Debt/Equity 0.28x
Stability
36 /100
Moderate Rev. volatility 124.15%
EPS volatility 24.75%
Profitable years 0
Ρωτήστε το StockBot για 2162.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Bo Chen
Employees
1,625
Headquarters
Chengdu
Επερχόμενα γεγονότα
19 ΑΥΓ
Earnings
Upcoming earnings report